1 / 26

Management of acute coronary syndromes in developing countries: The ACCESS registry

Management of acute coronary syndromes in developing countries: The ACCESS registry. Mohamed SOBHY (Egypt), Norka ANTEPARA (Venezuela), Alvaro ESCOBAR (Colombia), Samir ALAM (Lebanon), Alain LEIZOROVICZ (France), Carlos MARTINEZ (Mexico), José NICOLAU (Brazil), Gilles MONTALESCOT (France),

daniel-sanders
Download Presentation

Management of acute coronary syndromes in developing countries: The ACCESS registry

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Management of acute coronary syndromes in developing countries: The ACCESS registry Mohamed SOBHY (Egypt), Norka ANTEPARA (Venezuela), Alvaro ESCOBAR (Colombia), Samir ALAM (Lebanon), Alain LEIZOROVICZ (France), Carlos MARTINEZ (Mexico), José NICOLAU (Brazil), Gilles MONTALESCOT (France), on behalf of the ACCESS investigators

  2. Participating Countries

  3. Funding & disclosures • The ACCESS registry is sponsored by sanofi-aventis, Paris, France

  4. Disclosure • I have no disclosure

  5. ACCESS: background • The burden of cardiovascular diseases is predicted to escalate in developing countries. Study aim • To investigate the descriptive epidemiology, practice patterns, and primary outcomes of patients hospitalized with an acute coronary syndrome (ACS) in countries in Latin America, the Middle East, and North and South Africa.

  6. ACCESS: study design • Prospective, observational, multinational registry in patients hospitalized for an ACS (Jan 2007- Jan 2008). • Patients enrolled at 134 sites in 19 countries in • Latin America: Argentina, Brazil, Colombia, Dominican Republic, Ecuador, Guatemala, Mexico, Venezuela • Middle East: Egypt, Iran, Jordan, Kuwait, Lebanon, Saudi Arabia, United Arab Emirates • North Africa: Algeria, Morocco, Tunisia • South Africa

  7. ACCESS: study population • Patients (age ≥21 years) admitted alive to hospital with: • ischaemic symptoms of ACS within 24 hours of presentation, and • At least 1 of the following: • ECG changes: transient ST or ST ≥1 mm, new T-wave inversion ≥1 mm, pseudonormalization of previously inverted T waves, new Q-waves, new R wave S wave in lead V1, or new left bundle branch block • documentation of coronary artery disease • Elevated troponin or CK-MB concentration • Data at baseline, discharge and at 6+ 1 mo., 12+ 1mo. Follow up.

  8. ACCESS: endpoints12-months from hospitalization • Primary endpoint: all-cause death • Secondary endpoints: • cardiovascular death • cardiovascular death & non-fatal MI • non-fatal stroke • non-fatal MI • CV death, stroke, or MI & rehospitalization for ischaemic events • bleeding episodes

  9. ACCESS: results • 9732 ACS patients with 1-year follow-up • Discharge diagnoses: • STEMI 45% • NSTE ACS 52% • NSTEMI 24% • Unstable angina 28%

  10. ACCESS: baseline characteristics

  11. ACCESS: risk factors

  12. ACCESS: laboratory data

  13. ACCESS: in-hospital medications

  14. ACCESS: in-hospital antithrombotic therapy

  15. ACCESS: in-hospital interventions

  16. ACCESS: reperfusion in STEMI *94% with stent; 39% with drug-eluting stent

  17. ACCESS: medications at discharge

  18. ACCESS: death at 12 months *P<0.05 for NSTE ACS vs STEMI

  19. ACCESS: cause of death

  20. ACCESS: Survival curves NSTE ACS vs STEMI P <0.0001

  21. ACCESS: 12-month events *P ≤0.05 NSTE ACS vs STEMI †Endpoint: CV death, non-fatal stroke or MI

  22. Main factors* associated with 12-month death (n=8788) OR (95% CI) 8.9 (6.2, 12.8) Cardiac arrest Cardiogenic shock Stroke/TIA Age >70 years 5.6 (3.9, 8.0) 3.2 (1.8, 5.7) 2.2 (1.8, 2.7) 0 2 4 6 8 10 12 14 *Four strongest independent factors among 17

  23. ACCESS: conclusions • In this multinational, observational study of ACS patients, use of evidence-based pharmacological therapies for ACS was quite high, but reperfusion rates for STEMI (40%) were disappointingly low. • These findings suggest opportunities to reduce further the risk of long-term ischaemic events in ACS patients in developing countries.

  24. Acknowledgements Principal Investigator:Gilles MONTALESCOT (France) Steering Committee:Norka ANTEPARA (Venezuela), Alvaro ESCOBAR (Colombia), Samir ALAM (Lebanon), Alain LEIZOROVICZ (France), Carlos MARTINEZ (Mexico), José NICOLAU (Brazil), Mohamed SOBHY (Egypt) National Coordinators:Oscar BAZZINO (Argentina), Wilson RAMIREZ (Dominican Republic), Ricarddo MARMOL (Ecuador), Ismael GUZMAN (Guatemala), Wael ALMAHMEED (UAE), Mohammed ZUBAID (Kuwait), Ashraf HAMMOUDA (Saudi Arabia), Gholamreza Davoodi (Iran), Akram AL SALEH (Jordan), Mohand HADDAK(Algeria), Abdelhamid MOUSTAGHFIR (Morocco), Rachid MECHMECH (Tunisia), Colin SCHAMROTH (South Africa) And all Study Investigatorswho participated in the ACCESS Registry

  25. Thank YOU

  26. See you next year! June 2012

More Related